Biotech company Biogen (NASDAQ:BIIB) reported revenue ahead of Wall Street’s expectations in Q1 CY2026, with sales up 1.9% ...

Biotech company Biogen (NASDAQ:BIIB) will be reporting results this Wednesday before the bell. Here’s what you need to know.

Biogen has agreed to acquire ​Apellis ​Pharmaceuticals ​for about $5.6 billion in cash, expanding its portfolio ⁠of ‌rare-disease medicines.

Biogen Inc (NASDAQ:BIIB) reported upbeat earnings for the third quarter on Wednesday. The company pisted third-quarter adjusted EPS of $4.08, down 6%, beating the consensus of $3.79. The company ...

Biogen Inc. (NASDAQ:BIIB) reported on Thursday that the first quarter of 2025 adjusted earnings per share was $3.02. That’s down from $3.67 a year ago, beating the analyst consensus of $2.52. The ...

Oct 2 (Reuters) - In a rare – and possibly unique – turn of events, both pharmacy company Biogen (BIIB.O), opens new tab and its shareholders have asked a federal appeals court to grant mid-case ...

Biogen is an intriguing stock that occupies one of the leading positions in the central nervous system therapeutic market. On May 1, it released fairly strong financial results for the first quarter ...

Biogen posted fourth-quarter revenue and profit that topped expectations as its cost cuts showed progress and new products, including its breakthrough Alzheimer's treatment Leqembi, saw growth. The ...

Sage Therapeutics is rated a Strong Buy due to its undervaluation, trading below cash holdings, and potential in its drug pipeline, especially Zuranolone. Biogen's $7.22 per share buyout offer signals ...

AI-generated summary reviewed by our newsroom. Read our AI Policy. Biogen plans to beef up its Research Triangle Park operations with $2 billion in new local spending, the company announced Monday.

Cambridge-based biopharmaceutical company Sage Therapeutics filed a lawsuit against their partner, the biotechnology company Biogen, after rejecting their $469 million buy-out proposal late last month ...